CoChat

TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models

Open access

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Variants in triggering receptor expressed on myeloid cells 2 (TREM2) confer high risk for Alzheimer’s disease (AD) and other neurodegenerative diseases. However, the cell types and mechanisms underlying TREM2’s involvement in neurodegeneration remain to be established. Here, we report that TREM2 is up-regulated on myeloid cells surrounding amyloid deposits in AD mouse models and human AD tissue. TREM2 was detected on CD45hiLy6C+ myeloid cells, but not on P2RY12+ parenchymal microglia. In AD mice deficient for TREM2, the CD45hiLy6C+ macrophages are virtually eliminated, resulting in reduced inflammation and ameliorated amyloid and tau pathologies. These data suggest a functionally important role for TREM2+ macrophages in AD pathogenesis and an unexpected, detrimental role of TREM2 in AD pathology. These findings have direct implications for future development of TREM2-targeted therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20142322

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. TREM2 expression is increased around Aβ plaques. (a) A novel Trem2 knockout with a LacZ reporter under the control of the Trem2 promoter was generated. (b–m) TREM2 IHC was performed in WT mice at 2 (b), 4 (c), 6 (d), and 12 mo (e) of age, in APPPS1 mice at 2 (f), 4 (g), 6 (h), and 12 mo (i) of age, and in 5XFAD mice at 2 (j), 4 (k), 6 (l), and 8 mo (m) of age (n = 4–5). Insets show Congo red costaining with arrows indicating plaques. (n–q) TREM2 was also observed around plaques (n, p, and q) but not in regions lacking Aβ deposition (o) in human AD cases (n = 2). Arrows point to Congo red–positive plaques. (r) TREM2 immunoreactivity was not observed in APPPS1;Trem2−/− mice (n = 7). Insets show Congo red costaining with arrows indicating plaques. (s and t) TREM2 expression was also assessed by qRT-PCR (s; two-way ANOVA, age P = 0.083, genotype P = 0.0036, interaction P = 0.185; Bonferroni-corrected Student’s t tests shown; n = 6–8 per group) and Western blot (t; n = 2–3). Arrowhead indicates position of TREM2-specific band. Error bars indicate SEM. *, P < 0.05. At least three independent experiments were performed for all analyses. Bars, 100 µm (bars in b and n apply to b–p and r).
Figure 1. TREM2 expression is increased around Aβ plaques. (a) A novel Trem2 knockout with a LacZ reporter under the control of the Trem2 promoter was generated. (b–m) TREM2 IHC was performed in WT mice at 2 (b), 4 (c), 6 (d), and 12 mo (e) of age, in APPPS1 mice at 2 (f), 4 (g), 6 (h), and 12 mo (i) of age, and in 5XFAD mice at 2 (j), 4 (k), 6 (l), and 8 mo (m) of age (n = 4–5). Insets show Congo red costaining with arrows indicating plaques. (n–q) TREM2 was also observed around plaques (n, p, and q) but not in regions lacking Aβ deposition (o) in human AD cases (n = 2). Arrows point to Congo red–positive plaques. (r) TREM2 immunoreactivity was not observed in APPPS1;Trem2−/− mice (n = 7). Insets show Congo red costaining with arrows indicating plaques. (s and t) TREM2 expression was also assessed by qRT-PCR (s; two-way ANOVA, age P = 0.083, genotype P = 0.0036, interaction P = 0.185; Bonferroni-corrected Student’s t tests shown; n = 6–8 per group) and Western blot (t; n = 2–3). Arrowhead indicates position of TREM2-specific band. Error bars indicate SEM. *, P < 0.05. At least three independent experiments were performed for all analyses. Bars, 100 µm (bars in b and n apply to b–p and r).CC BY-NC-SA · PubMed Central
Figure 2. TREM2 is expressed in plaque-associated myeloid cells. (a) In situ hybridization with TREM2 probes colocalized with Iba1 (n = 2). (b) X-gal staining of brain tissue from 4-mo-old APPPS1;Trem2LacZ/+ mice colocalized with fluorescent IHC for Iba1 and 6E10 (n = 3). (c–f) Confocal microscopy was used to assess TREM2 colocalization with 6E10+ plaque-associated myeloid cells (c; Iba1), astrocytes (d; GFAP), neurons (e; MAP2), or oligodendrocytes (f; MBP; n = 8). At least two independent experiments were performed for all analyses. Bars: (a) 20 µm; (b–f) 50 µm.
Figure 2. TREM2 is expressed in plaque-associated myeloid cells. (a) In situ hybridization with TREM2 probes colocalized with Iba1 (n = 2). (b) X-gal staining of brain tissue from 4-mo-old APPPS1;Trem2LacZ/+ mice colocalized with fluorescent IHC for Iba1 and 6E10 (n = 3). (c–f) Confocal microscopy was used to assess TREM2 colocalization with 6E10+ plaque-associated myeloid cells (c; Iba1), astrocytes (d; GFAP), neurons (e; MAP2), or oligodendrocytes (f; MBP; n = 8). At least two independent experiments were performed for all analyses. Bars: (a) 20 µm; (b–f) 50 µm.CC BY-NC-SA · PubMed Central
Figure 3. TREM2 is specifically expressed on CD11b+CD45hiF4/80+ macrophages in AD mice. (a and b) Isolated brain myeloid cells were gated on CD11b (a) and divided into CD45lo and CD45hi populations (b). (c and f) TREM2+ cells were exclusively CD45hi (c) and F4/80+ (f; n = 41). (d and e) TREM2 expression was quantified on CD45lo and CD45hi populations in APPPS1 mice (d; two-way ANOVA, age P < 0.0001; genotype/cell type P < 0.0001, interaction P < 0.0001; Bonferroni-corrected Student’s t tests shown; n = 2–8), 5XFAD mice (e; two-way ANOVA, age P = 0.025, genotype/cell type P < 0.0001, interaction P = 0.0003; Bonferroni-corrected Student’s t tests shown; n = 5–9), and WT controls (d and e; n = 4–14). Error bars indicate SEM. **, P < 0.01; ***, P < 0.001. (g and h) Flow cytometry on APPPS1;Trem2−/− mice (g) revealed a lack of TREM2+ cells compared with APPPS1;Trem2+/+ mice (h; n = 7). At least two independent experiments were performed for all analyses.
Figure 3. TREM2 is specifically expressed on CD11b+CD45hiF4/80+ macrophages in AD mice. (a and b) Isolated brain myeloid cells were gated on CD11b (a) and divided into CD45lo and CD45hi populations (b). (c and f) TREM2+ cells were exclusively CD45hi (c) and F4/80+ (f; n = 41). (d and e) TREM2 expression was quantified on CD45lo and CD45hi populations in APPPS1 mice (d; two-way ANOVA, age P < 0.0001; genotype/cell type P < 0.0001, interaction P < 0.0001; Bonferroni-corrected Student’s t tests shown; n = 2–8), 5XFAD mice (e; two-way ANOVA, age P = 0.025, genotype/cell type P < 0.0001, interaction P = 0.0003; Bonferroni-corrected Student’s t tests shown; n = 5–9), and WT controls (d and e; n = 4–14). Error bars indicate SEM. **, P < 0.01; ***, P < 0.001. (g and h) Flow cytometry on APPPS1;Trem2−/− mice (g) revealed a lack of TREM2+ cells compared with APPPS1;Trem2+/+ mice (h; n = 7). At least two independent experiments were performed for all analyses.CC BY-NC-SA · PubMed Central
Figure 4. Plaque-associated myeloid cells are reduced in TREM2-deficient mice. (a–c) Confocal microscopy was used to examine Iba1 and 6E10 expression in 4-mo-old APPPS1;Trem2−/− mice (b) and APPPS1;Trem2+/+ controls (a; quantified in c). (d and e) IHC and Congo red costaining (arrows) was performed for Ly6C in APPPS1;Trem2+/+ mice (d) and APPPS1;Trem2−/− animals (e). (a, b, d, and e) Insets show higher-magnification images. (f–h) CD45 and Congo red staining (arrows) was performed in human AD tissue (f; n = 2), APPPS1;Trem2+/+ mice (g), and APPPS1;Trem2−/− mice (h). (i–k) P2RY12 and Congo red staining (arrows) was performed in human AD tissue (i; n = 2), APPPS1;Trem2+/+ mice (j), and APPPS1;Trem2−/− animals (k). (l) TREM2 colocalized with CD45 but not P2RY12. (m–o) qRT-PCR was performed on whole brain lysates to examine transcript levels of myeloid cell markers (m), proinflammatory cytokines (n), and antiinflammatory markers (o). All experiments used n = 7–8 mice per group unless otherwise noted, and at least two independent experiments were performed for all analyses. Error bars indicate SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Bars: (a and b) 50 µm; (d–l) 20 µm.
Figure 4. Plaque-associated myeloid cells are reduced in TREM2-deficient mice. (a–c) Confocal microscopy was used to examine Iba1 and 6E10 expression in 4-mo-old APPPS1;Trem2−/− mice (b) and APPPS1;Trem2+/+ controls (a; quantified in c). (d and e) IHC and Congo red costaining (arrows) was performed for Ly6C in APPPS1;Trem2+/+ mice (d) and APPPS1;Trem2−/− animals (e). (a, b, d, and e) Insets show higher-magnification images. (f–h) CD45 and Congo red staining (arrows) was performed in human AD tissue (f; n = 2), APPPS1;Trem2+/+ mice (g), and APPPS1;Trem2−/− mice (h). (i–k) P2RY12 and Congo red staining (arrows) was performed in human AD tissue (i; n = 2), APPPS1;Trem2+/+ mice (j), and APPPS1;Trem2−/− animals (k). (l) TREM2 colocalized with CD45 but not P2RY12. (m–o) qRT-PCR was performed on whole brain lysates to examine transcript levels of myeloid cell markers (m), proinflammatory cytokines (n), and antiinflammatory markers (o). All experiments used n = 7–8 mice per group unless otherwise noted, and at least two independent experiments were performed for all analyses. Error bars indicate SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Bars: (a and b) 50 µm; (d–l) 20 µm.CC BY-NC-SA · PubMed Central
Figure 5. TREM2 deficiency reduces Aβ accumulation. (a) IHC with 6E10 was performed on brain slices from 4-mo-old APPPS1;Trem2+/+ and APPPS1;Trem2−/− mice (quantified in c; n = 7–8). (b) Analysis of ThioS plaque number revealed similar results (quantified in d; n = 7–8). (a and b) Insets show a higher magnification of the hippocampus. Bar, 1 mm. (e) APP and Aβ levels were assessed by Western blot using 6E10. (f and g) Quantified relative to GAPDH, there was no significant change in APP protein levels (f) but a significant reduction in Aβ (g) in APPPS1;Trem2−/− mice (n = 3–4). (h and i) ELISAs on brain lysates also showed a significant reduction in insoluble Aβ42 and a trend toward a reduction in soluble Aβ42 (h) and a trend toward a reduction in soluble and insoluble Aβ40 (i; n = 3–4). #, P < 0.10; *, P < 0.05; ***, P < 0.001. At least two independent experiments were performed for all analyses.
Figure 5. TREM2 deficiency reduces Aβ accumulation. (a) IHC with 6E10 was performed on brain slices from 4-mo-old APPPS1;Trem2+/+ and APPPS1;Trem2−/− mice (quantified in c; n = 7–8). (b) Analysis of ThioS plaque number revealed similar results (quantified in d; n = 7–8). (a and b) Insets show a higher magnification of the hippocampus. Bar, 1 mm. (e) APP and Aβ levels were assessed by Western blot using 6E10. (f and g) Quantified relative to GAPDH, there was no significant change in APP protein levels (f) but a significant reduction in Aβ (g) in APPPS1;Trem2−/− mice (n = 3–4). (h and i) ELISAs on brain lysates also showed a significant reduction in insoluble Aβ42 and a trend toward a reduction in soluble Aβ42 (h) and a trend toward a reduction in soluble and insoluble Aβ40 (i; n = 3–4). #, P < 0.10; *, P < 0.05; ***, P < 0.001. At least two independent experiments were performed for all analyses.CC BY-NC-SA · PubMed Central
Figure 6. TREM2 deficiency reduces astrocytosis and MAPT phosphorylation. (a and b) Astrocytosis was assessed in 4-mo-old APPPS1;Trem2+/+ (a) and APPPS1;Trem2−/− mice (b) using IHC for GFAP and 6E10 (n = 7–8). (c and f) The number of GFAP+ cells surrounding plaques was quantified (c; n = 3–4), and results were confirmed by qRT-PCR (f; n = 7–8). (d, e, g, and h) Hyperphosphorylated MAPT was detected in APPPS1;Trem2−/− (e and h) and APPPS1;Trem2+/+ mice (d and g) with AT8 (d and e) and AT180 antibodies (g and h; n = 7–8). Arrows indicate Congo red–positive plaques. (i) Quantification of the area of AT180 immunoreactivity revealed significant decreases in APPPS1;Trem2−/− mice (n = 3–4). At least two independent experiments were performed for all analyses. Error bars indicate SEM. *, P < 0.05; **, P < 0.01. Bar, 50 µm.
Figure 6. TREM2 deficiency reduces astrocytosis and MAPT phosphorylation. (a and b) Astrocytosis was assessed in 4-mo-old APPPS1;Trem2+/+ (a) and APPPS1;Trem2−/− mice (b) using IHC for GFAP and 6E10 (n = 7–8). (c and f) The number of GFAP+ cells surrounding plaques was quantified (c; n = 3–4), and results were confirmed by qRT-PCR (f; n = 7–8). (d, e, g, and h) Hyperphosphorylated MAPT was detected in APPPS1;Trem2−/− (e and h) and APPPS1;Trem2+/+ mice (d and g) with AT8 (d and e) and AT180 antibodies (g and h; n = 7–8). Arrows indicate Congo red–positive plaques. (i) Quantification of the area of AT180 immunoreactivity revealed significant decreases in APPPS1;Trem2−/− mice (n = 3–4). At least two independent experiments were performed for all analyses. Error bars indicate SEM. *, P < 0.05; **, P < 0.01. Bar, 50 µm.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

33 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 683

Metadata

Authors
Jay, T. R., Miller, C. M., Cheng, P. J., Graham, L. C., Bemiller, S., Broihier, M. L., Xu, G., Margevicius, D., Karlo, J. C., Sousa, G. L., Cotleur, A. C., Butovsky, O., Bekris, L., Staugaitis, S. M., Leverenz, J. B., Pimplikar, S. W., Landreth, G. E., Howell, G. R., Ransohoff, R. M., & Lamb, B. T.
Affiliations
  • Cleveland Clinic (US)
  • The Lerner Research Institute 1 and 2
  • Jackson Laboratory (US)
  • Case Western Reserve University (US)
  • Brigham and Women's Hospital (US)
Corresponding author
Lamb, Bruce T.
Venue
Journal of Experimental Medicine
Published
2015-03-02
Volume
212
Issue
3
Pages
287-295
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2155344647
Cited by
682
References
33
Citations by year
2026: 27 · 2025: 56 · 2024: 46 · 2023: 56 · 2022: 74 · 2021: 62 · 2020: 70 · 2019: 59 · 2018: 65 · 2017: 67 · 2016: 54 · 2015: 45
FWCI
41.06
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion, cc-by-nc-sa)
Funders
  • National Institutes of Health (UL1TR000439)
  • National Institute on Aging (R01AG023012, AG023012, F31AG048704)
  • National Institute of General Medical Sciences (T32GM007250)
  • National Institute of Neurological Disorders and Stroke (NS047804, T32NS067431, NS087298, R01NS088137, T32NS077888)
  • National Center for Advancing Translational Sciences
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
Keywords
TREM2, Alzheimer's disease, inflammatory macrophages, microglia, amyloid deposits, tau pathology, neuroinflammation, amyloidosis
MeSH terms
Age Factors, Aged, Alzheimer Disease, Animals, Disease Models, Animal, Female, Hippocampus, Humans, Macrophages, Male, Membrane Glycoproteins, Mice, Transgenic, Receptors, Immunologic, Up-Regulation, Amyloid beta-Peptides, tau Proteins, Leukocyte Common Antigens

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. https://app.cochat.ai/papers/10.1084/jem.20142322
The paper
Jay, T. R., Miller, C. M., Cheng, P. J., Graham, L. C., Bemiller, S., Broihier, M. L., Xu, G., Margevicius, D., Karlo, J. C., Sousa, G. L., Cotleur, A. C., Butovsky, O., Bekris, L., Staugaitis, S. M., Leverenz, J. B., Pimplikar, S. W., Landreth, G. E., Howell, G. R., Ransohoff, R. M., & Lamb, B. T. (2015). TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20142322

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.